Age | Gender | Gender for malignancy | ||||||
---|---|---|---|---|---|---|---|---|
F | F | M | M | |||||
< 50 | > 50 | Female | Male | < 57 | > 57 | < 56 | > 56 | |
Total n. patients | 2553 | 1484 | 2397 | 1640 | 1857 | 540 | 1266 | 374 |
Malignancy (n, 45) | 4 | 41 | 12 | 33 | 1 | 11 | 5 | 28 |
OR | 1.12 | 4.40 | 1.12 | 1.12 | ||||
[95% CI] | [1.09, 1.15] | [2.24, 8.62] | [1.06, 1.18] | [1.08, 1.16] | ||||
AUC | 0.775 | 0.665 | 0.841 | 0.871 | ||||
[95% CI] | [0.721, 0.829] | [0.651, 0.680] | [0.826, 0.856] | [0.854, 0.887] | ||||
Sensitivity | 91.11% | 73.33% | 91.67% | 84.85% | ||||
[95% CI] | [78.8, 97.5] | [58.1, 85.4] | [61.5, 99.8] | [68.1, 94.9] | ||||
Specificity | 65.53% | 59.74% | 77.82% | 78.47% | ||||
[95% CI] | [64.0, 67.0] | [58.2, 61.3] | [76.1, 79.5] | [76.4—80.5] | ||||
LR+ | 2.64 | 1.82 | 4.13 | 3.94 | ||||
[95% CI] | [2.4, 2.9] | [1.5, 2.2] | [3.4, 5.0] | [3.3—4.7] | ||||
LR- | 0.14 | 0.45 | 0.11 | 0.19 | ||||
[95% CI] | [0.05, 0.3] | [0.3, 0.7] | [0.02, 0.7] | 0.09—0.4 |